<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:55:02Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10084601" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10084601</identifier>
        <datestamp>2023-04-11</datestamp>
        <setSpec>arthresther</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Arthritis Res Ther</journal-id>
              <journal-title-group>
                <journal-title>Arthritis Research &amp; Therapy</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1478-6354</issn>
              <issn pub-type="epub">1478-6362</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10084601</article-id>
              <article-id pub-id-type="pmcid">PMC10084601</article-id>
              <article-id pub-id-type="pmc-uid">10084601</article-id>
              <article-id pub-id-type="pmid">37038159</article-id>
              <article-id pub-id-type="publisher-id">3027</article-id>
              <article-id pub-id-type="doi">10.1186/s13075-023-03027-5</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9475-9362</contrib-id>
                  <name>
                    <surname>Baraliakos</surname>
                    <given-names>Xenofon</given-names>
                  </name>
                  <address>
                    <email>xenofon.baraliakos@elisabethgruppe.de</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ranza</surname>
                    <given-names>Roberto</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Östör</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ciccia</surname>
                    <given-names>Francesco</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coates</surname>
                    <given-names>Laura C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rednic</surname>
                    <given-names>Simona</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Walsh</surname>
                    <given-names>Jessica A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Douglas</surname>
                    <given-names>Kevin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gao</surname>
                    <given-names>Tianming</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kato</surname>
                    <given-names>Koji</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Song</surname>
                    <given-names>In-Ho</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ganz</surname>
                    <given-names>Fabiana</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Deodhar</surname>
                    <given-names>Atul</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.476674.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0559 133X</institution-id><institution>Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, </institution></institution-wrap>Claudiusstr. 45, 44649 Herne, Germany </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411284.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 4647 6936</institution-id><institution>Serviço de Reumatología, Hospital de Clinicas, </institution><institution>Universidade Federal de Uberlândia, </institution></institution-wrap>Uberlândia, Minas Gerais Brazil </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.1002.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id><institution>Monash University, Cabrini Hospital &amp; Emeritus Research, </institution></institution-wrap>Melbourne &amp; ANU, Canberra, Australia </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.9841.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2200 8888</institution-id><institution>University of Campania Luigi Vanvitelli, </institution></institution-wrap>Caserta, Italy </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.411040.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0571 5814</institution-id><institution>Rheumatology Department, </institution><institution>Iuliu Hatieganu University of Medicine and Pharmacy, </institution></institution-wrap>Cluj-Napoca, Romania </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.280807.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9555 3716</institution-id><institution>Salt Lake City Veterans Affairs Health, </institution></institution-wrap>Salt Lake City, UT USA </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.223827.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 0096</institution-id><institution>University of Utah Health, </institution></institution-wrap>Salt Lake City, UT USA </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.431072.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 4227</institution-id><institution>AbbVie Inc, </institution></institution-wrap>North Chicago, IL USA </aff>
                <aff id="Aff10"><label>10</label>AbbVie Inc, Baar, Switzerland </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution>Oregon Health &amp; Science University, </institution></institution-wrap>Portland, OR USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>10</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>10</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2023</year>
              </pub-date>
              <volume>25</volume>
              <elocation-id>56</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>8</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients randomized to upadacitinib 15 mg (UPA15), placebo (switched to UPA15 at week 24), or adalimumab 40 mg (ADA; SELECT-PsA 1 only). Axial involvement was determined by investigator judgement (yes or no; based on the totality of available clinical information, such as duration and characteristics of back pain, age of onset, and previous lab investigations and imaging, if available) alone, or investigator judgement and patient-reported outcome (PRO)-based criteria (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] ≥ 4 and BASDAI Q2 ≥ 4). Efficacy outcomes that describe axial disease activity, including BASDAI endpoints, such as change from baseline in the overall BASDAI score or proportion of patients achieving BASDAI50 (≥ 50% improvement from baseline), as well as Ankylosing Spondylitis Disease Activity Score (ASDAS) endpoints, such as mean change from baseline in overall ASDAS or proportion of patients achieving ASDAS inactive disease or low disease activity, were evaluated at weeks 12, 24, and 56, with nominal <italic>P</italic>-values shown. Treatment-emergent adverse events (TEAEs) are summarized through week 56.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">30.9% of patients in SELECT-PsA 1 and 35.7% in SELECT-PsA 2 had axial involvement by investigator judgement alone; 22.6% (SELECT-PsA 1) and 28.6% (SELECT-PsA 2) had axial involvement by investigator judgement and PRO-based criteria. Greater proportions of patients achieved BASDAI50 with UPA15 versus placebo using either criterion, and versus ADA using investigator judgement alone, at week 24 in SELECT-PsA 1 (investigator alone: UPA15, 59.0%, placebo, 26.9%, <italic>P</italic> &lt; 0.0001, ADA, 44.1%, <italic>P</italic> = 0.015; investigator and PRO-based: UPA15, 60.4%, placebo, 29.3%, <italic>P</italic> &lt; 0.0001, ADA, 47.1%, <italic>P</italic> = 0.074), with comparable findings in SELECT-PsA 2. Similar results were observed with UPA15 for additional BASDAI and ASDAS endpoints at weeks 12 and 24, with improvements maintained at week 56. Rates of TEAEs were generally similar across sub-groups irrespective of axial involvement status.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">PsA patients with axial involvement determined by predefined criteria showed greater BASDAI and ASDAS responses with UPA15 versus placebo, and numerically similar/greater responses versus ADA. Safety results were generally comparable between patients with or without axial involvement.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par5">ClinicalTrials.gov: SELECT-PsA 1, NCT03104400; SELECT-PsA 2, NCT0310437.</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1186/s13075-023-03027-5.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Adalimumab</kwd>
                <kwd>Ankylosing Spondylitis Disease Activity Score (ASDAS)</kwd>
                <kwd>Axial involvement</kwd>
                <kwd>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</kwd>
                <kwd>Janus kinase (JAK) inhibitor</kwd>
                <kwd>Psoriatic arthritis (PsA)</kwd>
                <kwd>Safety</kwd>
                <kwd>Upadacitinib</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par58">Currently, there are no commonly accepted criteria for identifying axial involvement in psoriatic arthritis (PsA), and prevalence rates range from 5 to 70% depending on the criteria used for diagnosis and disease duration [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Despite this lack of consensus, identifying and effectively treating PsA patients with axial involvement remains an important clinical topic. Registry data suggest that PsA patients with axial involvement had higher disease activity and greater impairment in quality of life compared to PsA patients without axial involvement [<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, axial involvement in PsA responds differently to certain treatments compared to peripheral PsA [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, a better understanding of clinical responses in patients with PsA and axial involvement can help optimize treatment decisions.</p>
              <p id="Par59">The efficacy of upadacitinib, an oral Janus kinase (JAK) inhibitor, to treat adults with active PsA or axial spondyloarthritis (axSpA) has been established in phase 3 clinical trials, with a consistent long-term safety profile observed across rheumatoid arthritis, PsA, and axSpA [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. Given the observed benefits of upadacitinib for the treatment of PsA, and the need to better understand clinical responses in PsA patients with axial involvement, the objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in patients with active PsA and axial involvement from the phase 3 SELECT-PsA trials.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par60">Full methodological details for SELECT-PsA 1 (NCT03104400) and SELECT-PsA 2 (NCT03104374), including study dates and size, inclusion/exclusion criteria, randomization and blinding, and concomitant treatments have been published previously [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p>
              <sec id="Sec3">
                <title>Patients and trial design</title>
                <p id="Par61">Adults (≥ 18 years) with a clinical diagnosis of active PsA, who also fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR), [<xref ref-type="bibr" rid="CR24">24</xref>] and had an inadequate response or intolerance to ≥ 1 non-biologic disease-modifying antirheumatic drug (non-bDMARD) (SELECT-PsA 1) or ≥ 1 bDMARD (SELECT-PsA 2) were eligible for inclusion in these trials. Patients were randomized to receive blinded once daily oral upadacitinib 15 mg or upadacitinib 30 mg, placebo, or every other week subcutaneous adalimumab 40 mg (SELECT-PsA 1 only) for 24 weeks. At week 24, patients assigned to placebo at baseline were switched to blinded upadacitinib 15 mg or 30 mg. Blinding was maintained until all patients reached week 56. Open-label long-term extensions are currently ongoing for both trials (SELECT-PsA 1 up to 5 years; SELECT-PsA 2 up to 3 years).</p>
                <p id="Par62">Both studies were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. As per Good Clinical Practice (GCP), the trial protocols were approved by an independent ethics committee (IEC)/institutional review board (IRB). All patients provided written informed consent.</p>
              </sec>
              <sec id="Sec4">
                <title>Axial involvement</title>
                <p id="Par63">At baseline, axial involvement was determined by investigator judgement (yes or no) based on the totality of available clinical information, such as duration and characteristics of back pain, age of onset, and previous lab investigations and imaging, if available. For these studies, imaging was not required to confirm axial disease. In addition to investigator judgement, a second set of patient-reported outcome (PRO)-based criteria for active axial inflammatory involvement were applied: overall BASDAI score ≥ 4 and BASDAI question 2 (“<italic>How would you describe the overall level of AS (ankylosing spondylitis) neck, back, or hip pain you have had?</italic>”) score ≥ 4 at baseline [<xref ref-type="bibr" rid="CR25">25</xref>].</p>
              </sec>
              <sec id="Sec5">
                <title>Outcomes</title>
                <p id="Par64">Efficacy outcomes that describe axial disease activity in the two PsA patient sub-groups with axial involvement (ie, axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria) were evaluated at weeks 12, 24, and 56 for both studies. Efficacy endpoints included change from baseline in the overall BASDAI score, modified BASDAI score (excluding question 3 related to peripheral joint pain), and the Ankylosing Spondylitis Disease Activity Score (ASDAS [CRP], hereafter referred to as ASDAS). In addition, change from baseline in individual BASDAI components (questions 1 to 6) were evaluated. The proportion of patients achieving BASDAI50 (≥ 50% improvement from baseline in BASDAI), as well as ASDAS inactive disease (ID, defined as score &lt; 1.3), ASDAS low disease activity (LDA, defined as score &lt; 2.1), ASDAS major improvement (MI, defined as ≥ 2.0 decrease from baseline), and ASDAS clinically important improvement (CII, defined as ≥ 1.1 decrease from baseline) were also assessed.</p>
                <p id="Par65">For this post-analysis, safety data from both SELECT-PsA trials were summarized for all patients who received ≥ 1 dose of study drug through week 56. Treatment-emergent adverse events (TEAEs) were coded per the Medical Dictionary for Regulatory Activities (MedDRA; v 22.0) and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; v 5.0). Deaths and cardiovascular events were adjudicated by a blinded, independent, external committee using definitions that were pre-specified. Reported gastrointestinal (GI) perforations were adjudicated by a blinded committee of sponsor-employed experts.</p>
              </sec>
              <sec id="Sec6">
                <title>Statistical analysis</title>
                <p id="Par66">For this post-hoc analysis, efficacy endpoints were summarized for randomized patients who received at least one dose of trial drug. Data from patients treated with placebo, upadacitinib 15 mg, and adalimumab 40 mg (SELECT-PsA 1 only) at weeks 12 and 24 are presented, as well as placebo switched to upadacitinib 15 mg, continuous upadacitinib 15 mg, and adalimumab 40 mg (SELECT-PsA 1 only) at week 56. As upadacitinib 15 mg is the approved dose for patients with active PsA, [<xref ref-type="bibr" rid="CR26">26</xref>] baseline demographics and efficacy data from patients treated with continuous upadacitinib 30 mg are not shown.</p>
                <p id="Par67">Continuous efficacy endpoints (change from baseline in overall BASDAI, modified BASDAI, individual BASDAI components, and ASDAS) were assessed using mixed-effect model for repeated measures (MMRM) analysis with unstructured variance–covariance matrix, including treatment, visit, treatment-by-visit interaction, and the stratification factor current DMARD use (yes/no) as fixed factors, and the continuous fixed covariate of baseline measurement. Least squares means with 95% confidence intervals (CIs) are provided for the continuous efficacy endpoints. The MMRM analysis for week 24 excluded data collected after premature discontinuation of the study drug. Binary efficacy endpoints (proportions of patients achieving BASDAI50, ASDAS ID, ASDAS LDA, ASDAS MI, and ASDAS CII) were analyzed using Cochran-Mantel–Haenszel tests adjusted for the main stratification factor of current DMARD use (yes/no). Binary efficacy endpoints are summarized as response rates with 95% CIs. Non-responder imputation (NRI) was used for missing data handling of binary endpoints. Differences between upadacitinib 15 mg and placebo at weeks 12 and 24 (SELECT-PsA 1 and SELECT-PsA 2), as well as upadacitinib 15 mg and adalimumab at weeks 12, 24, and 56 (SELECT-PsA 1 only), were based on nominal <italic>P</italic> values and were not multiplicity controlled. All data were analyzed using SAS version 9.4 (Cary, NC, USA).</p>
                <p id="Par68">Exposure-adjusted event rates (EAERs; events per 100 patient-years) of TEAEs (with 95% CIs) are summarized for patients who received ≥ 1 dose of study drug through week 56 in SELECT-PsA 1 and SELECT-PsA 2. Data for upadacitinib 15 mg (including patients who were assigned to placebo at baseline and switched to upadacitinib 15 mg treatment at week 24) and adalimumab (SELECT-PsA 1 only) are shown across all sub-groups (ie, without axial involvement, with axial involvement defined by investigator judgement alone, or with axial involvement defined by investigator judgement and PRO-based criteria).</p>
              </sec>
            </sec>
            <sec id="Sec7">
              <title>Results</title>
              <sec id="Sec8">
                <title>Patient sub-groups and baseline status</title>
                <p id="Par69">Of the patient populations in each study (excluding continuous upadacitinib 30 mg), 30.9% (<italic>n</italic> = 396/1281) of PsA patients in SELECT-PsA 1 (non-bDMARD-IR [inadequate response]) and 35.7% (<italic>n</italic> = 151/423) of patients in SELECT-PsA 2 (bDMARD-IR) were defined as having axial involvement based on investigator judgement alone. Based on investigator judgement and PRO-based criteria, 22.6% (<italic>n</italic> = 290/1281) of PsA patients in SELECT-PsA 1 and 28.6% (<italic>n</italic> = 121/423) of patients in SELECT-PsA 2 were defined as having axial involvement (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A, B). Mean age at baseline was slightly higher in the bDMARD-IR sub-groups regardless of axial involvement (range: 51.9 to 54.5 years old; non-bDMARD-IR range: 50.0 to 51.5 years old), over half of patients in each sub-group were female (range: 50.3 to 56.3%), and the majority of patients were White (range: 84.1 to 90.5%) (Table <xref rid="Tab1" ref-type="table">1</xref>). At baseline, PsA patients with axial involvement based on either criterion showed marginally higher disease burden than patients without axial involvement, but other baseline characteristics were comparable across all groups. By definition, patients with axial involvement defined by both investigator judgement and PRO-based criteria had higher BASDAI scores at baseline than those defined by investigator judgement alone.<fig id="Fig1"><label>Fig. 1</label><caption><p>Proportion of PsA Patients With Axial Involvement Defined by Investigator Judgement Alone or Investigator Judgement and PRO-Based Criteria. <sup>a</sup>Sub-groups shown include the following treatments from SELECT-PsA 1: placebo, adalimumab, and upadacitinib 15 mg; upadacitinib 30 mg is excluded. <sup>b</sup>Sub-groups shown include the following treatments from SELECT-PsA 2: placebo and upadacitinib 15 mg; upadacitinib 30 mg is excluded. ADA, adalimumab; bDMARD, biologic disease-modifying antirheumatic drug; IR, inadequate response; PBO, placebo; PRO, patient-reported outcome; PsA, psoriatic arthritis; UPA, upadacitinib</p></caption><graphic xlink:href="13075_2023_3027_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline Demographics and Disease Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"><bold>Parameter, mean (SD)</bold><sup>c</sup></th><th align="left" colspan="3"><bold>SELECT-PsA 1 (non-bDMARD-IR)</bold><sup>a</sup></th><th align="left" colspan="3"><bold>SELECT-PsA 2 (bDMARD-IR)</bold><sup>b</sup></th></tr><tr><th align="left">Without Axial Involvement<break/>(<italic>n</italic> = 885)</th><th align="left">Axial Involvement by Investigator Alone<break/>(<italic>n</italic> = 396)</th><th align="left">Axial Involvement by Investigator + PRO-Based<break/>(<italic>n</italic> = 290)</th><th align="left">Without Axial Involvement<break/>(<italic>n</italic> = 272)</th><th align="left">Axial Involvement by Investigator Alone<break/>(<italic>n</italic> = 151)</th><th align="left">Axial Involvement by Investigator + PRO-Based<break/>(<italic>n</italic> = 121)</th></tr></thead><tbody><tr><td align="left">Age, years</td><td align="left">51.5 (11.7)</td><td align="left">50.1 (13.0)</td><td align="left">50.0 (12.7)</td><td align="left">54.5 (11.6)</td><td align="left">51.9 (12.0)</td><td align="left">52.2 (11.9)</td></tr><tr><td align="left" colspan="7">Sex, n (%)</td></tr><tr><td align="left"> Female</td><td align="left">472 (53.3)</td><td align="left">199 (50.3)</td><td align="left">153 (52.8)</td><td align="left">153 (56.3)</td><td align="left">80 (53.0)</td><td align="left">67 (55.4)</td></tr><tr><td align="left"> Male</td><td align="left">413 (46.7)</td><td align="left">197 (49.7)</td><td align="left">137 (47.2)</td><td align="left">119 (43.8)</td><td align="left">71 (47.0)</td><td align="left">54 (44.6)</td></tr><tr><td align="left" colspan="7">Race, n (%)</td></tr><tr><td align="left"> American Indian or Alaska Native</td><td align="left">2 (0.2)</td><td align="left">2 (0.5)</td><td align="left">1 (0.3)</td><td align="left">2 (0.7)</td><td align="left">1 (0.7)</td><td align="left">1 (0.8)</td></tr><tr><td align="left"> Asian</td><td align="left">71 (8.0)</td><td align="left">44 (11.1)</td><td align="left">27 (9.3)</td><td align="left">19 (7.0)</td><td align="left">17 (11.3)</td><td align="left">10 (8.3)</td></tr><tr><td align="left"> Black or African American</td><td align="left">1 (0.1)</td><td align="left">5 (1.3)</td><td align="left">4 (1.4)</td><td align="left">7 (2.6)</td><td align="left">5 (3.3)</td><td align="left">4 (3.3)</td></tr><tr><td align="left"> Multiple</td><td align="left">9 (1.0)</td><td align="left">6 (1.5)</td><td align="left">6 (2.1)</td><td align="left">0</td><td align="left">1 (0.7)</td><td align="left">1 (0.8)</td></tr><tr><td align="left"> Native Hawaiian or Other Pacific Islander</td><td align="left">1 (0.1)</td><td align="left">2 (0.5)</td><td align="left">1 (0.3)</td><td align="left">2 (0.7)</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> White</td><td align="left">801 (90.5)</td><td align="left">337 (85.1)</td><td align="left">251 (86.6)</td><td align="left">242 (89.0)</td><td align="left">127 (84.1)</td><td align="left">105 (86.8)</td></tr><tr><td align="left" colspan="7">Ethnicity, n (%)</td></tr><tr><td align="left"> Hispanic or Latino/a</td><td align="left">146 (16.5)</td><td align="left">44 (11.1)</td><td align="left">37 (12.8)</td><td align="left">52 (19.1)</td><td align="left">37 (24.5)</td><td align="left">30 (24.8)</td></tr><tr><td align="left"> Not Hispanic or Latino/a</td><td align="left">739 (83.5)</td><td align="left">352 (88.9)</td><td align="left">253 (87.2)</td><td align="left">220 (80.9)</td><td align="left">114 (75.5)</td><td align="left">91 (75.2)</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">30.5 (7.0)</td><td align="left">30.1 (6.5)</td><td align="left">30.5 (6.4)</td><td align="left">31.5 (7.1)</td><td align="left">31.8 (8.1)</td><td align="left">32.6 (8.4)</td></tr><tr><td align="left">Duration of PsA diagnosis, years</td><td align="left">6.0 (7.1)</td><td align="left">6.3 (7.2)</td><td align="left">6.9 (7.7)</td><td align="left">10.5 (9.5)</td><td align="left">9.9 (9.2)</td><td align="left">10.4 (9.7)</td></tr><tr><td align="left">Duration of PsA symptoms, years</td><td align="left">8.9 (8.5)</td><td align="left">9.9 (9.0)</td><td align="left">10.0 (8.9)</td><td align="left">13.8 (10.9)</td><td align="left">12.7 (9.4)</td><td align="left">13.0 (9.9)</td></tr><tr><td align="left">Overall BASDAI</td><td align="left">5.3 (2.2)</td><td align="left">5.8 (2.0)</td><td align="left">6.7 (1.5)</td><td align="left">5.9 (2.2)</td><td align="left">6.2 (2.0)</td><td align="left">6.9 (1.4)</td></tr><tr><td align="left"> BASDAI Q2 (neck, back, or hip pain)<sup>d</sup></td><td align="left">4.6 (3.2)</td><td align="left">5.8 (2.8)</td><td align="left">7.1 (1.6)</td><td align="left">5.5 (3.2)</td><td align="left">6.4 (2.7)</td><td align="left">7.4 (1.7)</td></tr><tr><td align="left"> BASDAI Q3 (pain in joints other than neck, back, or hip)<sup>d</sup></td><td align="left">5.9 (2.6)</td><td align="left">6.1 (2.4)</td><td align="left">6.9 (1.9)</td><td align="left">6.2 (2.6)</td><td align="left">6.3 (2.3)</td><td align="left">6.9 (1.8)</td></tr><tr><td align="left">ASDAS (CRP)</td><td align="left">3.1 (1.0)</td><td align="left">3.4 (1.0)</td><td align="left">3.7 (0.8)</td><td align="left">3.2 (1.1)</td><td align="left">3.4 (1.0)</td><td align="left">3.6 (0.8)</td></tr><tr><td align="left">Patient’s assessment of pain<sup>d</sup></td><td align="left">6.0 (2.1)</td><td align="left">6.2 (2.0)</td><td align="left">6.7 (1.7)</td><td align="left">6.4 (2.2)</td><td align="left">6.6 (2.0)</td><td align="left">6.9 (1.8)</td></tr><tr><td align="left">Patient’s global assessment of disease activity<sup>d</sup></td><td align="left">6.4 (2.0)</td><td align="left">6.4 (2.1)</td><td align="left">7.0 (1.8)</td><td align="left">6.7 (2.0)</td><td align="left">7.0 (1.9)</td><td align="left">7.2 (1.8)</td></tr><tr><td align="left">Physician’s global assessment of disease activity<sup>d</sup></td><td align="left">6.5 (1.6)</td><td align="left">6.7 (1.7)</td><td align="left">6.9 (1.6)</td><td align="left">6.4 (1.8)</td><td align="left">6.7 (1.8)</td><td align="left">7.0 (1.6)</td></tr><tr><td align="left">TJC68</td><td align="left">19.3 (13.6)</td><td align="left">22.0 (15.6)</td><td align="left">23.5 (16.1)</td><td align="left">23.3 (16.7)</td><td align="left">28.2 (18.4)</td><td align="left">30.0 (18.8)</td></tr><tr><td align="left">SJC66</td><td align="left">11.1 (8.1)</td><td align="left">12.2 (10.1)</td><td align="left">12.8 (10.7)</td><td align="left">11.0 (8.0)</td><td align="left">12.9 (9.3)</td><td align="left">12.7 (9.7)</td></tr><tr><td align="left">Presence of dactylitis,<sup>e</sup> n (%)</td><td align="left">245 (27.7)</td><td align="left">144 (36.4)</td><td align="left">101 (34.8)</td><td align="left">64 (23.5)</td><td align="left">55 (36.4)</td><td align="left">45 (37.2)</td></tr><tr><td align="left">Presence of enthesitis,<sup>f</sup> n (%)</td><td align="left">665 (75.1)</td><td align="left">320 (80.8)</td><td align="left">236 (81.4)</td><td align="left">218 (80.1)</td><td align="left">128 (84.8)</td><td align="left">108 (89.3)</td></tr><tr><td align="left" colspan="7">BSA with psoriasis, n (%)</td></tr><tr><td align="left">  &lt; 3%</td><td align="left">460 (52.0)</td><td align="left">185 (46.7)</td><td align="left">128 (44.1)</td><td align="left">103 (37.9)</td><td align="left">59 (39.1)</td><td align="left">51 (42.1)</td></tr><tr><td align="left">  ≥ 3%</td><td align="left">425 (48.0)</td><td align="left">211 (53.3)</td><td align="left">162 (55.9)</td><td align="left">169 (62.1)</td><td align="left">92 (60.9)</td><td align="left">70 (57.9)</td></tr><tr><td align="left">hsCRP (mg/L)</td><td align="left">10.5 (14.2)</td><td align="left">12.6 (17.6)</td><td align="left">13.2 (19.0)</td><td align="left">11.0 (18.9)</td><td align="left">10.4 (17.8)</td><td align="left">11.6 (19.5)</td></tr></tbody></table><table-wrap-foot><p><italic>ASDAS</italic> Ankylosing Spondylitis Disease Activity Score, <italic>BASDAI</italic> Bath Ankylosing Spondylitis Disease Activity Index, <italic>bDMARD</italic> Biologic disease-modifying antirheumatic drug, <italic>BSA</italic> Body surface area, <italic>hsCRP</italic> High-sensitivity CRP, <italic>IR</italic> Inadequate response, <italic>PRO</italic> Patient-reported outcome, <italic>PsA</italic> Psoriatic arthritis, <italic>SJC66</italic> swollen joint count 66, <italic>TJC68</italic> Tender joint count 68</p><p><sup>a</sup>Sub-groups shown include the following treatments from SELECT-PsA 1: placebo, adalimumab, and upadacitinib 15 mg</p><p><sup>b</sup>Sub-groups shown include the following treatments from SELECT-PsA 2: placebo and upadacitinib 15 mg</p><p><sup>c</sup>Data presented as mean (SD) unless indicated</p><p><sup>d</sup>Measured via numeric rating scale, 0 to 10</p><p><sup>e</sup>As determined by Leeds Dactylitis Index &gt; 0</p><p><sup>f</sup>As determined by Total Enthesitis Count &gt; 0</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec9">
                <title>Efficacy endpoints</title>
                <p id="Par70">Overall BASDAI score improvements were greater with upadacitinib 15 mg versus placebo at weeks 12 and 24 in both studies and according to both criteria used to define axial involvement (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A, B), and versus adalimumab at week 24 in PsA patients with axial involvement defined by investigator judgement alone (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A). Mean change from baseline in modified BASDAI (excluding question 3 related to peripheral joint pain) was greater with upadacitinib 15 mg versus placebo in PsA patients with axial involvement defined by both criteria at both time points and across both studies (Fig. <xref rid="Fig2" ref-type="fig">2</xref>C, D). Results for the individual BASDAI components (questions 1 to 6) were similar and consistent with that observed for overall BASDAI and modified BASDAI (Supplementary Fig. S<xref rid="MOESM1" ref-type="media">1</xref>A-D, Supplementary Fig. S<xref rid="MOESM1" ref-type="media">2</xref>A-D), with a greater response observed for BASDAI question 2 (related to back pain) at week 24 with upadacitinib 15 mg versus adalimumab based on investigator judgement alone (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>C). A greater proportion of PsA patients achieved a BASDAI50 response with upadacitinib 15 mg versus placebo at weeks 12 and 24 in both studies regardless of the criteria used to define axial involvement (Fig. <xref rid="Fig2" ref-type="fig">2</xref>E, F), and versus adalimumab at week 24 based on investigator judgement alone (Fig. <xref rid="Fig2" ref-type="fig">2</xref>E). In general, clinical responses for overall BASDAI, modified BASDAI, and BASDAI50 were similar with upadacitinib 15 mg and adalimumab at week 12 but were numerically higher with upadacitinib 15 mg than adalimumab at week 24, irrespective of the criteria used to define axial involvement.<fig id="Fig2"><label>Fig. 2</label><caption><p>Mean Change From Baseline in Overall BASDAI and Modified BASDAI (Excluding Question 3) Scores, and Proportion of Patients Achieving BASDAI50, at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). Mean change from baseline in the overall BASDAI score (<bold>A</bold>) or modified BASDAI (excluding question 3—How would you describe the overall level of pain/swelling in joints other than neck, back, or hips you have had?) score (<bold>C</bold>) at weeks 12 and 24 for PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1. Mean change from baseline in overall BASDAI (<bold>B</bold>) or modified BASDAI (<bold>D</bold>) at weeks 12 and 24 for PsA patients with axial involvement defined by either criterion treated with placebo or upadacitinib 15 mg QD from SELECT-PsA 2. Proportions of PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria that achieved BASDAI50 at weeks 12 and 24 treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1 (<bold>E</bold>) or with placebo or upadacitinib 15 mg QD from SELECT-PsA 2 (<bold>F</bold>). Overall BASDAI and modified BASDAI were analyzed using mixed-effect model for repeated measures and are shown as least squares means with 95% CIs. BASDAI50 was analyzed using Cochran-Mantel–Haenszel tests with non-responder imputation and shown as response rates with 95% CIs. ****<italic>P</italic> &lt; 0.0001, ***<italic>P</italic> &lt; 0.001, *<italic>P</italic> &lt; 0.05 upadacitinib 15 mg versus placebo; <sup>#</sup><italic>P</italic> &lt; 0.05, upadacitinib 15 mg versus adalimumab; nominal <italic>P</italic> values are shown and were not multiplicity controlled. ADA, adalimumab; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI50, ≥ 50% improvement from baseline in BASDAI; bDMARD, biologic disease-modifying antirheumatic drug; CI, confidence interval; EOW, every other week; IR, inadequate response; PBO, placebo; PRO, patient-reported outcome; PsA, psoriatic arthritis; QD, once daily; UPA, upadacitinib</p></caption><graphic xlink:href="13075_2023_3027_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par71">In both studies, greater improvements in ASDAS scores were observed with upadacitinib 15 mg versus placebo at weeks 12 and 24 according to both criteria used to define axial involvement (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A, B). A greater improvement in the ASDAS score was also observed with upadacitinib 15 mg versus adalimumab at week 24 in PsA patients with axial involvement defined by investigator judgement alone (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A). More PsA patients with axial involvement achieved ASDAS ID with upadacitinib 15 mg versus placebo based on either criterion at weeks 12 and 24 in SELECT PsA 1 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>C) and at week 24 in SELECT-PsA 2 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>D); results were numerically greater with upadacitinib 15 mg versus placebo at week 12 in SELECT-PsA 2. Greater proportions of PsA patients with axial involvement in both studies achieved ASDAS LDA with upadacitinib 15 mg versus placebo, as well as ASDAS MI (Supplementary Fig. S<xref rid="MOESM1" ref-type="media">3</xref>A, B) and ASDAS CII (Supplementary Fig. S<xref rid="MOESM1" ref-type="media">3</xref>C, D), at both timepoints and according to both criteria (Fig. <xref rid="Fig3" ref-type="fig">3</xref>E, F). In addition, greater proportions of PsA patients with axial involvement treated with upadacitinib 15 mg versus adalimumab achieved ASDAS MI (investigator alone) or ASDAS CII (both criteria) at week 24 (Supplementary Fig. S<xref rid="MOESM1" ref-type="media">3</xref>A, C). As stated above for the BASDAI efficacy endpoints, ASDAS and ASDAS responses (ID, LDA, MI, and CII) were similar with upadacitinib 15 mg and adalimumab at week 12 but were numerically higher with upadacitinib 15 mg than adalimumab at week 24, according to both criteria.<fig id="Fig3"><label>Fig. 3</label><caption><p>Mean Change From Baseline in ASDAS Scores, and Proportion of Patients Achieving ASDAS Inactive Disease (ID) and ASDAS Low Disease Activity (LDA), at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). Mean change from baseline in ASDAS (CRP) scores at weeks 12 and 24 for PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1 (<bold>A</bold>) or with placebo or upadacitinib 15 mg QD from SELECT-PsA 2 (<bold>B</bold>). Proportions of PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW that achieved ASDAS ID (<bold>C</bold>) or ASDAS LDA (<bold>E</bold>) at weeks 12 and 24 from SELECT-PsA 1. Proportions of PsA patients with axial involvement defined by either criterion treated with placebo or upadacitinib 15 mg QD that achieved ASDAS ID (<bold>D</bold>) or ASDAS LDA (<bold>F</bold>) at weeks 12 and 24 from SELECT-PsA 2. ASDAS ID defined as score &lt; 1.3; LDA defined as score &lt; 2.1. ASDAS was analyzed using mixed-effect model for repeated measures and are shown as least squares means with 95% CIs. ASDAS ID and ASDAS LDA were analyzed using Cochran-Mantel–Haenszel tests with non-responder imputation and are shown as response rates with 95% CIs. ****<italic>P</italic> &lt; 0.0001, ***<italic>P</italic> &lt; 0.001, **<italic>P</italic> &lt; 0.01, upadacitinib 15 mg versus placebo; <sup>##</sup><italic>P</italic> &lt; 0.01, upadacitinib 15 mg versus adalimumab; nominal <italic>P</italic> values are shown and were not multiplicity controlled. ADA, adalimumab; ASDAS, Ankylosing Spondylitis Disease Activity Score; bDMARD, biologic disease-modifying antirheumatic drug; CI, confidence interval; EOW, every other week; ID, inactive disease; IR, inadequate response; LDA, low disease activity; PBO, placebo; PRO, patient-reported outcome; PsA, psoriatic arthritis; QD, once daily; UPA, upadacitinib</p></caption><graphic xlink:href="13075_2023_3027_Fig3_HTML" id="MO3"/></fig></p>
                <p id="Par72">Long-term assessment of BASDAI and ASDAS efficacy endpoints in PsA patients with axial involvement treated with upadacitinib 15 mg demonstrated that the clinical improvements observed at weeks 12 and 24 were maintained at week 56 in both studies based on both criteria (Supplementary Table S<xref rid="MOESM1" ref-type="media">1</xref>, Supplementary Table S<xref rid="MOESM1" ref-type="media">2</xref>). Furthermore, PsA patients treated with upadacitinib 15 mg showed consistent numerically higher responses than adalimumab across the efficacy endpoints regardless of the criteria used to define axial involvement.</p>
              </sec>
              <sec id="Sec10">
                <title>Safety</title>
                <p id="Par73">In this post-hoc analysis of PsA patients with or without axial involvement from SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR), the safety profile of upadacitinib 15 mg though week 56 (Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>, respectively) was generally similar to previously published data from the full study populations [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR22">22</xref>]. Overall, rates of TEAEs were generally similar across sub-groups irrespective of axial involvement status, with only a few differences to note. Compared to patients without axial involvement, patients with axial involvement (defined by either criterion) treated with upadacitinib 15 mg had lower rates of any serious adverse event or any infection, but higher rates of hepatic disorder and anemia in the non-bDMARD-IR population (Table <xref rid="Tab2" ref-type="table">2</xref>), while lower rates of hepatic disorder, but higher rates of opportunistic infection, creatine phosphokinase (CPK) elevation, any malignancy, and malignancy excluding non-melanoma skin cancer (NMSC) in the bDMARD-IR population (Table <xref rid="Tab3" ref-type="table">3</xref>). In SELECT-PsA 1, rates of any serious adverse event and hepatic disorder were higher with adalimumab, while anemia was higher with upadacitinib 15 mg, in patients with axial involvement compared to those without; serious infection and CPK elevation were higher with upadacitinib 15 mg versus adalimumab in patients without axial involvement compared to those with axial involvement (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of Safety Data Through Week 56 From SELECT-PsA 1 (non-bDMARD-IR)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">EAER, E/100 PY<sup>a</sup><break/>(95% CI)</th><th align="left" colspan="2">Without Axial Involvement</th><th align="left" colspan="2">Investigator Alone</th><th align="left" colspan="2">Investigator + PRO-Based</th></tr><tr><th align="left">UPA 15 mg QD<sup>b</sup><break/>(<italic>n</italic> = 411; PY = 572.1)</th><th align="left">ADA 40 mg EOW<break/>(<italic>n</italic> = 302; PY = 448.3)</th><th align="left">UPA 15 mg QD<sup>b</sup><break/>(<italic>n</italic> = 206; PY = 267.0)</th><th align="left">ADA 40 mg EOW<break/>(<italic>n</italic> = 127; PY = 183.1)</th><th align="left">UPA 15 mg QD<sup>b</sup><break/>(<italic>n</italic> = 158; PY = 206.9)</th><th align="left">ADA 40 mg EOW<break/>(<italic>n</italic> = 85;<break/>PY = 122.9)</th></tr></thead><tbody><tr><td align="left">Any AE</td><td align="left">283.7 (270.1, 297.8)</td><td align="left">247.2 (232.8, 262.1)</td><td align="left">275.7 (256.1, 296.3)</td><td align="left">311.9 (286.8, 338.5)</td><td align="left">280.3 (258.0, 304.1)</td><td align="left">335.2 (303.6, 369.2)</td></tr><tr><td align="left">Any serious AE</td><td align="left">10.1 (7.7, 13.1)</td><td align="left">8.3 (5.8, 11.4)</td><td align="left">6.7 (4.0, 10.7)</td><td align="left">12.0 (7.5, 18.2)</td><td align="left">7.7 (4.4, 12.6)</td><td align="left">15.5 (9.3, 24.1)</td></tr><tr><td align="left"><p>Any AE leading to discontinuation</p><p>of study drug</p></td><td align="left">4.7 (3.1, 6.9)</td><td align="left">7.8 (5.4, 10.9)</td><td align="left">4.5 (2.3, 7.9)</td><td align="left">6.6 (3.4, 11.4)</td><td align="left">4.3 (2.0, 8.3)</td><td align="left">8.1 (3.9, 15.0)</td></tr><tr><td align="left">All deaths (n/100 PY)<sup>c</sup></td><td align="left">0.3 (0.0, 1.3)</td><td align="left">0</td><td align="left">0</td><td align="left">0.5 (0.0, 3.0)</td><td align="left">0</td><td align="left">0.8 (0.0, 4.5)</td></tr><tr><td align="left" colspan="7">AEs of special interest</td></tr><tr><td align="left"> Any infection</td><td align="left">100.3 (92.3, 108.9)</td><td align="left">70.5 (62.9, 78.7)</td><td align="left">83.1 (72.6, 94.8)</td><td align="left">72.6 (60.8, 86.1)</td><td align="left">80.7 (68.9, 93.9)</td><td align="left">73.2 (58.9, 90.0)</td></tr><tr><td align="left"> Serious infection</td><td align="left">3.1 (1.9, 5.0)</td><td align="left">0.9 (0.2, 2.3)</td><td align="left">2.2 (0.8, 4.9)</td><td align="left">2.2 (0.6, 5.6)</td><td align="left">2.4 (0.8, 5.6)</td><td align="left">2.4 (0.5, 7.1)</td></tr><tr><td align="left"> Opportunistic infection<sup>d</sup></td><td align="left">0.3 (0.0, 1.3)</td><td align="left">0</td><td align="left">0.4 (0.0, 2.1)</td><td align="left">0</td><td align="left">0.5 (0.0, 2.7)</td><td align="left">0</td></tr><tr><td align="left"> Herpes zoster</td><td align="left">3.7 (2.3, 5.6)</td><td align="left">0.7 (0.1, 2.0)</td><td align="left">4.5 (2.3, 7.9)</td><td align="left">0</td><td align="left">4.8 (2.3, 8.9)</td><td align="left">0</td></tr><tr><td align="left"> Active tuberculosis</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">   GI perforation (adjudicated)</td><td align="left">0.3 (0.0, 1.3)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> Hepatic disorder</td><td align="left">16.6 (13.4, 20.3)</td><td align="left">19.0 (15.1, 23.4)</td><td align="left">24.3 (18.8, 31.0)</td><td align="left">39.3 (30.8, 49.5)</td><td align="left">27.5 (20.9, 35.7)</td><td align="left">45.6 (34.4, 59.2)</td></tr><tr><td align="left"> Anemia</td><td align="left">1.9 (1.0, 3.4)</td><td align="left">1.3 (0.5, 2.9)</td><td align="left">5.2 (2.9, 8.8)</td><td align="left">2.2 (0.6, 5.6)</td><td align="left">4.3 (2.0, 8.3)</td><td align="left">1.6 (0.2, 5.9)</td></tr><tr><td align="left"> Neutropenia</td><td align="left">2.3 (1.2, 3.9)</td><td align="left">3.8 (2.2, 6.1)</td><td align="left">2.6 (1.1, 5.4)</td><td align="left">5.5 (2.6, 10.0)</td><td align="left">2.9 (1.1, 6.3)</td><td align="left">4.9 (1.8, 10.6)</td></tr><tr><td align="left"> Lymphopenia</td><td align="left">2.6 (1.5, 4.3)</td><td align="left">0.2 (0.0, 1.2)</td><td align="left">4.5 (2.3, 7.9)</td><td align="left">0</td><td align="left">2.4 (0.8, 5.6)</td><td align="left">0</td></tr><tr><td align="left"> CPK elevation</td><td align="left">12.8 (10.0, 16.0)</td><td align="left">5.8 (3.8, 8.5)</td><td align="left">10.1 (6.7, 14.7)</td><td align="left">10.9 (6.7, 16.9)</td><td align="left">10.1 (6.3, 15.5)</td><td align="left">11.4 (6.2, 19.1)</td></tr><tr><td align="left"> Renal dysfunction</td><td align="left">0</td><td align="left">0</td><td align="left">0.7 (0.1, 2.7)</td><td align="left">0</td><td align="left">0.5 (0.0, 2.7)</td><td align="left">0</td></tr><tr><td align="left"> Any malignancy</td><td align="left">1.1 (0.4, 2.3)</td><td align="left">0.7 (0.1, 2.0)</td><td align="left">1.1 (0.2, 3.3)</td><td align="left">1.6 (0.3, 4.8)</td><td align="left">1.5 (0.3, 4.3)</td><td align="left">0.8 (0.0, 4.5)</td></tr><tr><td align="left"> Malignancy (excl. NMSC)</td><td align="left">0.5 (0.1, 1.5)</td><td align="left">0.7 (0.1, 2.0)</td><td align="left">0.7 (0.1, 2.7)</td><td align="left">0.5 (0.0, 3.0)</td><td align="left">1.0 (0.1, 3.5)</td><td align="left">0.8 (0.0, 4.5)</td></tr><tr><td align="left"> NMSC</td><td align="left">0.7 (0.2, 1.8)</td><td align="left">0</td><td align="left">0.4 (0.0, 2.1)</td><td align="left">1.1 (0.1, 4.0)</td><td align="left">0.5 (0.0, 2.7)</td><td align="left">0</td></tr><tr><td align="left"> Lymphoma</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> MACE (adjudicated)<sup>e</sup></td><td align="left">0.5 (0.1, 1.5)</td><td align="left">0.2 (0.0, 1.2)</td><td align="left">0</td><td align="left">1.1 (0.1, 4.0)</td><td align="left">0</td><td align="left">1.6 (0.2, 5.9)</td></tr><tr><td align="left"> VTE (adjudicated)<sup>f</sup></td><td align="left">0.3 (0.0, 1.3)</td><td align="left">0.2 (0.0, 1.2)</td><td align="left">0.4 (0.0, 2.1)</td><td align="left">0.6 (0.0, 3.1)</td><td align="left">0.5 (0.0, 2.7)</td><td align="left">0.8 (0.0, 4.6)</td></tr></tbody></table><table-wrap-foot><p><italic>ADA</italic> Adalimumab, <italic>AE</italic> Adverse event, <italic>bDMARD</italic> Biologic disease-modifying antirheumatic drug, <italic>CI</italic> Confidence interval, <italic>CPK</italic> Creatine phosphokinase, <italic>E</italic> Event, <italic>EAER</italic> Exposure-adjusted event rate, <italic>EOW</italic> Every other week, <italic>IR</italic> Inadequate response, <italic>MACE</italic> Major adverse cardiovascular event, <italic>NMSC</italic> Non-melanoma skin cancer, <italic>PsA</italic> Psoriatic arthritis, <italic>PY</italic> Patient-years, <italic>QD</italic> Once daily, <italic>UPA</italic> Upadacitinib, <italic>VTE</italic> Venous thromboembolism</p><p><sup>a</sup>Safety data presented as events per 100 patient-years (with 95% CIs), unless indicated</p><p><sup>b</sup>Patients in the UPA 15 mg QD group include those who were assigned to UPA 15 mg QD at baseline, as well as those switched from placebo to UPA 15 mg QD at week 24</p><p><sup>c</sup>Two deaths were reported with upadacitinib 15 mg from the sub-group without axial involvement, one death with adalimumab from the investigator alone sub-group, and one death with adalimumab from the investigator judgement and PRO-based sub-group</p><p><sup>d</sup>Opportunistic infections excluding tuberculosis and herpes zoster</p><p><sup>e</sup>Major adverse cardiovascular events defined as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death</p><p><sup>f</sup>Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism (PE) (fatal and non-fatal)</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of Safety Data Through Week 56 From SELECT-PsA 2 (bDMARD-IR)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">EAER, E/100 PY<sup>a</sup><break/>(95% CI)</th><th align="left">Without Axial Involvement</th><th align="left">Investigator<break/>Alone</th><th align="left">Investigator + <break/>PRO-Based</th></tr><tr><th align="left">UPA 15 mg QD<sup>b</sup><break/>(<italic>n</italic> = 184; PY = 272.5)</th><th align="left">UPA 15 mg QD<sup>b</sup><break/>(<italic>n</italic> = 106; PY = 146.9)</th><th align="left">UPA 15 mg QD<sup>b</sup><break/>(<italic>n</italic> = 81; PY = 113.4)</th></tr></thead><tbody><tr><td align="left">Any AE</td><td align="left">259.8 (241.0, 279.7)</td><td align="left">262.1 (236.6, 289.6)</td><td align="left">254.0 (225.5, 285.1)</td></tr><tr><td align="left">Any serious AE</td><td align="left">12.5 (8.6, 17.4)</td><td align="left">17.7 (11.6, 25.9)</td><td align="left">18.5 (11.5, 28.3)</td></tr><tr><td align="left">Any AE leading to discontinuation of study drug</td><td align="left">11.0 (7.4, 15.7)</td><td align="left">8.2 (4.2, 14.3)</td><td align="left">7.9 (3.6, 15.1)</td></tr><tr><td align="left">All deaths (n/100 PY)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left" colspan="4">AEs of special interest</td></tr><tr><td align="left"> Any infection</td><td align="left">91.0 (80.0, 103.1)</td><td align="left">87.1 (72.7, 103.6)</td><td align="left">82.0 (66.2, 100.5)</td></tr><tr><td align="left"> Serious infection</td><td align="left">2.9 (1.3, 5.8)</td><td align="left">2.0 (0.4, 6.0)</td><td align="left">1.8 (0.2, 6.4)</td></tr><tr><td align="left"> Opportunistic infection<sup>c</sup></td><td align="left">0.4 (0.0, 2.0)</td><td align="left">1.4 (0.2, 4.9)</td><td align="left">1.8 (0.2, 6.4)</td></tr><tr><td align="left"> Herpes zoster</td><td align="left">4.0 (2.0, 7.2)</td><td align="left">3.4 (1.1, 7.9)</td><td align="left">3.5 (1.0, 9.0)</td></tr><tr><td align="left"> Active tuberculosis</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> GI perforation (adjudicated)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> Hepatic disorder</td><td align="left">5.9 (3.4, 9.5)</td><td align="left">2.7 (0.7, 7.0)</td><td align="left">2.6 (0.5, 7.7)</td></tr><tr><td align="left"> Anemia</td><td align="left">2.6 (1.0, 5.3)</td><td align="left">1.4 (0.2, 4.9)</td><td align="left">1.8 (0.2, 6.4)</td></tr><tr><td align="left"> Neutropenia</td><td align="left">1.5 (0.4, 3.8)</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> Lymphopenia</td><td align="left">1.1 (0.2, 3.2)</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> CPK elevation</td><td align="left">4.4 (2.3, 7.7)</td><td align="left">6.8 (3.3, 12.5)</td><td align="left">7.9 (3.6, 15.1)</td></tr><tr><td align="left"> Renal dysfunction</td><td align="left">0.7 (0.1, 2.7)</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> Any malignancy</td><td align="left">1.5 (0.4, 3.8)</td><td align="left">4.2 (1.5, 9.1)</td><td align="left">5.4 (2.0, 11.8)</td></tr><tr><td align="left"> Malignancy (excl. NMSC)</td><td align="left">0.4 (0.0, 2.0)</td><td align="left">2.7 (0.7, 7.0)</td><td align="left">3.5 (1.0, 9.0)</td></tr><tr><td align="left"> NMSC</td><td align="left">1.1 (0.2, 3.2)</td><td align="left">1.4 (0.2, 5.0)</td><td align="left">1.8 (0.2, 6.5)</td></tr><tr><td align="left"> Lymphoma</td><td align="left">0.7 (0.1, 2.7)</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left"> MACE (adjudicated)<sup>d</sup></td><td align="left">0</td><td align="left">0.7 (0.0, 3.8)</td><td align="left">0.9 (0.0, 5.0)</td></tr><tr><td align="left"> VTE (adjudicated)<sup>e</sup></td><td align="left">0.4 (0.0, 2.0)</td><td align="left">0</td><td align="left">0</td></tr></tbody></table><table-wrap-foot><p><italic>AE</italic> Adverse event, <italic>bDMARD</italic> Biologic disease-modifying antirheumatic drug, <italic>CI</italic> Confidence interval, <italic>CPK</italic> Creatine phosphokinase, <italic>E</italic> Event, <italic>EAER</italic> Exposure-adjusted event rate, <italic>EOW</italic> Every other week, <italic>IR</italic> Inadequate response, <italic>MACE</italic> Major adverse cardiovascular event, <italic>NMSC</italic> Non-melanoma skin cancer, <italic>PsA</italic> Psoriatic arthritis, <italic>PY</italic> Patient-years, <italic>QD</italic> Once daily, <italic>UPA</italic> Upadacitinib, <italic>VTE</italic> Venous thromboembolism</p><p><sup>a</sup>Safety data presented as events per 100 patient-years (with 95% CIs), unless indicated</p><p><sup>b</sup>Patients in the UPA 15 mg QD group include those who were assigned to UPA 15 mg QD at baseline, as well as those switched from placebo to UPA 15 mg QD at week 24</p><p><sup>c</sup>Opportunistic infections excluding tuberculosis and herpes zoster</p><p><sup>d</sup>Major adverse cardiovascular events defined as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death</p><p><sup>e</sup>Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism (PE) (fatal and non-fatal)</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec11">
              <title>Discussion</title>
              <p id="Par74">Here, we demonstrate that based on two different definitions of axial involvement, patients with active PsA and axial involvement had greater clinical responses for measures related to their axial symptoms (as determined by BASDAI and ASDAS) with upadacitinib 15 mg (approved dose) versus placebo at week 12, which were maintained or further improved at week 24 in both SELECT-PsA 1 (non-bDMARD-IR population) and SELECT-PsA 2 (bDMARD-IR population). In addition, SELECT-PsA 1 patients often had similar or greater numerical responses compared to adalimumab across multiple endpoints related to axial disease activity. Clinical improvements observed with upadacitinib 15 mg were maintained long-term at week 56. Responses were consistent across patient populations (non-bDMARD-IR and bDMARD-IR), endpoints (BASDAI, individual BASDAI components including question 2 related to back pain, and ASDAS), and assessments for axial involvement (investigator alone or investigator and PRO-based criteria), demonstrating support for inhibition of the JAK-STAT signaling pathway to improve axial symptoms in patients with active PsA. Complementary to the efficacy of upadacitinib in PsA with axial involvement, upadacitinib 15 mg reduced disease activity and axial inflammation (as detected by magnetic resonance imaging [MRI]), as well as improved function, in patients with AS or non-radiographic axial spondyloarthritis (nr-axSpA), providing further support from dedicated AS and axSpA studies for the efficacy of JAK inhibitors to treat axial disease [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p>
              <p id="Par75">PsA with axial involvement remains a topic of high clinical interest due to limited data on this specific patient population and no agreed upon classification or diagnostic criteria for axial involvement. Previous studies have utilized a variety of criteria to classify axial involvement in PsA, including applying CASPAR or Assessment of SpondyloArthritis international Society (ASAS) criteria, BASDAI cut-offs, presence of inflammatory back pain, sacroiliitis on imaging, and/or other criteria [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Given the lack of clear criteria, the presence of axial involvement (‘psoriatic spondylitis’) was determined by the investigators in the SELECT-PsA trials based on their judgement of the totality of clinical information that was available to them. We further strengthened the recognition of inflammatory axial involvement by applying PRO-based criteria (BASDAI score ≥ 4 and BASDAI question 2 score [AS neck, back, or hip pain] ≥ 4 at baseline) to confirm active axial disease in patients from the SELECT-PsA trials [<xref ref-type="bibr" rid="CR25">25</xref>]. This analysis shows that PsA patients with axial involvement treated with upadacitinib 15 mg using either of the predefined criteria showed improvements in measures of axial disease, including ASDAS and modified BASDAI (excluding question 3 related to peripheral joint pain).</p>
              <p id="Par76">In this post-hoc analysis of the SELECT-PsA trials, the safety profile of upadacitinib 15 mg was generally similar between patients with axial involvement using either criterion, as well as those without axial involvement. Minor variability in the rates of some TEAEs (eg, hepatic disorder in SELECT-PsA 1 [non-bDMARD-IR] or CPK elevation in SELECT-PsA 2 [bDMARD-IR]) were noted in patients with axial involvement, but no clear patterns were observed across the two studies. No new safety risks were identified with upadacitinib 15 mg treatment in this post-hoc analysis of the SELECT-PsA studies [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p>
              <p id="Par77">Potential limitations of this post-hoc analysis should also be considered. First, axial involvement in the SELECT-PsA trials was determined by investigator judgement and was not consistently confirmed by imaging in all patients. Improvements in active MRI inflammation in the spine and sacroiliac joints has been demonstrated previously with upadacitinib treatment in patients with AS or nr-axSpA [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In addition, similar to our analysis, the secukinumab MAXIMISE trial did not require imaging confirmation, but instead identified patients with PsA and axial manifestations based on CASPAR criteria, active spinal disease with a BASDAI score ≥ 4, and a spinal pain Visual Analogue Score ≥ 40/100 at baseline, with improvements in MRI scores observed (in patients with available imaging) in the spine and sacroiliac joints following treatment [<xref ref-type="bibr" rid="CR25">25</xref>]. Although the lack of imaging is a limitation of the SELECT-PsA trials, the diagnosis of axial involvement by treating physicians based on available clinical information does reflect real-world clinical practice, where imaging may not always be routinely conducted to confirm a diagnosis. In addition, HLA-B27 status, which has been identified more often in patients with axial involvement [<xref ref-type="bibr" rid="CR1">1</xref>] and has been associated with greater disease severity in PsA, was not assessed in either SELECT-PsA trial. Furthermore, as is common to post-hoc analyses, statistical comparisons for the BASDAI and ASDAS efficacy endpoints were not multiplicity controlled, and only nominal <italic>P</italic> values have been displayed in this manuscript.</p>
            </sec>
            <sec id="Sec12">
              <title>Conclusions</title>
              <p id="Par78">In summary, irrespective of the predefined assessment for axial involvement applied (investigator judgement alone or both investigator judgement and PRO-based criteria), patients with active PsA and axial involvement demonstrated improvements in their axial symptoms with upadacitinib 15 mg, often with greater numerical responses versus adalimumab, which were maintained over long-term follow-up (56 weeks) in two phase 3 studies. Safety results for upadacitinib 15 mg were generally comparable between patients with or without axial involvement. These data provide important information for treating clinicians on the efficacy and safety of upadacitinib 15 mg in axial disease and may help guide treatment decisions for PsA patients with axial involvement.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Information</title>
              <sec id="Sec13">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="13075_2023_3027_MOESM1_ESM.pdf">
                      <caption>
                        <p><bold>Additional file 1:</bold> <bold>Supplementary Fig. S1. </bold>BASDAI Components at Weeks 12 and 24 From SELECT-PsA 1(non-bDMARD-IR). <bold>Supplementary Fig. S2. </bold>BASDAI Components at Weeks 12 and 24 From SELECT-PsA 2 (bDMARD-IR). <bold>Supplementary Fig. S3. </bold>ASDAS Major Improvement (MI) and ASDAS Clinically Important Improvement (CII) at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). <bold>Supplementary Table S1. </bold>Efficacy Endpoints at Week 56 From SELECT-PsA 1 (non-bDMARD-IR). <bold>Supplementary Table S2. </bold>Efficacy Endpoints at Week 56 From SELECT-PsA 2 (bDMARD-IR). </p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>ACR</term>
                  <def>
                    <p id="Par6">American College of Rheumatology</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ADA</term>
                  <def>
                    <p id="Par7">Adalimumab</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AS</term>
                  <def>
                    <p id="Par8">Ankylosing spondylitis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ASADAS</term>
                  <def>
                    <p id="Par9">Ankylosing Spondylitis Disease Activity Score</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ASAS</term>
                  <def>
                    <p id="Par10">Assessment of SpondyloArthritis international Society</p>
                  </def>
                </def-item>
                <def-item>
                  <term>axSpA</term>
                  <def>
                    <p id="Par11">Axial spondyloarthritis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BASDAI</term>
                  <def>
                    <p id="Par12">Bath Ankylosing Spondylitis Disease Activity Index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BASDAI50</term>
                  <def>
                    <p id="Par13">≥ 50% Improvement from baseline in BASDAI</p>
                  </def>
                </def-item>
                <def-item>
                  <term>bDMARD</term>
                  <def>
                    <p id="Par14">Biologic disease-modifying antirheumatic drug</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BSA</term>
                  <def>
                    <p id="Par15">Body surface area</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CASPAR</term>
                  <def>
                    <p id="Par16">Classification Criteria for Psoriatic Arthritis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CI</term>
                  <def>
                    <p id="Par17">Confidence interval</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CII</term>
                  <def>
                    <p id="Par18">Clinically important improvement</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CPK</term>
                  <def>
                    <p id="Par19">Creatine phosphokinase</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CRP</term>
                  <def>
                    <p id="Par20">C-reactive protein</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CTCAE</term>
                  <def>
                    <p id="Par21">Common Terminology Criteria for Adverse Events</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DSA</term>
                  <def>
                    <p id="Par22">Data Sharing Agreement</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DVT</term>
                  <def>
                    <p id="Par23">Deep vein thrombosis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EAER</term>
                  <def>
                    <p id="Par24">Exposure-adjusted event rates</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EOW</term>
                  <def>
                    <p id="Par25">Every other week</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GCP</term>
                  <def>
                    <p id="Par26">Good Clinical Practice</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GI</term>
                  <def>
                    <p id="Par27">Gastrointestinal</p>
                  </def>
                </def-item>
                <def-item>
                  <term>hsCRP</term>
                  <def>
                    <p id="Par28">High-sensitivity CRP</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ICH</term>
                  <def>
                    <p id="Par29">International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ID</term>
                  <def>
                    <p id="Par30">Inactive disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IEC</term>
                  <def>
                    <p id="Par31">Independent ethics committee</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IR</term>
                  <def>
                    <p id="Par32">Inadequate response</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IRB</term>
                  <def>
                    <p id="Par33">Institutional review board</p>
                  </def>
                </def-item>
                <def-item>
                  <term>JAK</term>
                  <def>
                    <p id="Par34">Janus kinase</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LDA</term>
                  <def>
                    <p id="Par35">Low disease activity</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MACE</term>
                  <def>
                    <p id="Par36">Major adverse cardiovascular event</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MedDRA</term>
                  <def>
                    <p id="Par37">Medical Dictionary for Regulatory Activities</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MI</term>
                  <def>
                    <p id="Par38">Major improvement</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MMRM</term>
                  <def>
                    <p id="Par39">Mixed-effect model for repeated measures</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MRI</term>
                  <def>
                    <p id="Par40">Magnetic resonance imaging</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NMSC</term>
                  <def>
                    <p id="Par41">Non-melanoma skin cancer</p>
                  </def>
                </def-item>
                <def-item>
                  <term>nr-axSpA</term>
                  <def>
                    <p id="Par42">Non-radiographic axial spondyloarthritis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NRI</term>
                  <def>
                    <p id="Par43">Non-responder imputation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PBO</term>
                  <def>
                    <p id="Par44">Placebo</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PE</term>
                  <def>
                    <p id="Par45">Pulmonary embolism</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PRO</term>
                  <def>
                    <p id="Par46">Patient-reported outcome</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PsA</term>
                  <def>
                    <p id="Par47">Psoriatic arthritis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PY</term>
                  <def>
                    <p id="Par48">Patient-year(s)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>QD</term>
                  <def>
                    <p id="Par49">Once daily</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SAP</term>
                  <def>
                    <p id="Par50">Statistical Analysis Plan</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SJC66</term>
                  <def>
                    <p id="Par51">Swollen joint count 66</p>
                  </def>
                </def-item>
                <def-item>
                  <term>STAT</term>
                  <def>
                    <p id="Par52">Signal transducer and activator of transcription</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TEAE</term>
                  <def>
                    <p id="Par53">Treatment-emergent adverse event</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TJC68</term>
                  <def>
                    <p id="Par54">Tender joint count 68</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UPA</term>
                  <def>
                    <p id="Par55">Upadacitinib</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UPA15</term>
                  <def>
                    <p id="Par56">Upadacitinib 15 mg</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VTE</term>
                  <def>
                    <p id="Par57">Venous thromboembolism</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher’s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>AbbVie and the authors thank the patients, study sites, and investigators who participated in these clinical trials. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. The authors thank Jaclyn Anderson (employee of AbbVie) for her contributions to the design of the SELECT-PsA 1 and SELECT-PsA 2 clinical trials. Medical writing support was provided by Monica R.P. Elmore, PhD, of AbbVie. Editorial support was provided by Angela T. Hadsell of AbbVie. The investigator judgement alone data were originally presented at the American College of Rheumatology (ACR) Annual Meeting (virtual; November 5-9, 2020) [<xref ref-type="bibr" rid="CR32">32</xref>] and the investigator judgement and PRO-based criteria data were originally presented at the ACR 2021 Annual Meeting (virtual; November 5-9, 2021) [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authors’ contributions</title>
              <p>KK participated in the design of the studies. XB and RR participated in the acquisition of data as trial investigators. TG participated in the analysis of data. All authors participated in the interpretation of data. XB and FG contributed to the drafting of the manuscript. All authors contributed to the critical revision of the manuscript for important intellectual content and provided their approval of the final version for submission.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>AbbVie funded these trials and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. Medical writing support was provided by an employee of AbbVie.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (eg, protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</p>
              <p>These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: <ext-link ext-link-type="uri" xlink:href="https://www.abbvieclinicaltrials.com/hcp/data-sharing/.html">https://www.abbvieclinicaltrials.com/hcp/data-sharing/.html</ext-link><underline>.</underline></p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1">
                <title>Ethics approval and consent to participate</title>
                <p id="Par79">The SELECT-PsA 1 (NCT03104400) and SELECT-PsA 2 (NCT0310437) studies were conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, applicable regulations governing clinical trial conduct, and the Declaration of Helsinki 1964 and its later amendments. As per Good Clinical Practice (GCP), the trial protocols were approved by an independent ethics committee (IEC)/institutional review board (IRB). A full list of the IECs and IRBs for SELECT-PsA 1 and SELECT-PsA 2 have been published previously [<xref ref-type="bibr" rid="CR34">34</xref>]. All patients provided written informed consent.</p>
              </notes>
              <notes id="FPar2">
                <title>Consent for publication</title>
                <p id="Par80">Not applicable.</p>
              </notes>
              <notes id="FPar3" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par81">Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. XB: Received grant/research support from, consultant for, and is a member of speaker bureaus for AbbVie, Bristol Myers Squibb, Celgene, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB. RR: Consultant for AbbVie, Janssen, Novartis, and Pfizer; and is a member of speaker bureaus for AbbVie, Janssen, Novartis, and Pfizer. AÖ: Consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche; member of speaker bureaus for AbbVie, Bristol-Myers Squibb, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche. FC: Received grant/research support from AbbVie, Celgene, Pfizer, Roche, and UCB; consultant for AbbVie, Bristol-Myers Squibb, Celgene, MSD, Novartis, Pfizer, Janssen, Sanofi, Sandoz, Galapagos, Sobi, and UCB; member of speaker bureaus for AbbVie, Bristol-Myers Squibb, Celgene, Novartis, Pfizer, and UCB. LCC: Received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB; consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB; speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. SR: Received grant/research support from AbbVie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, and UCB; consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, and Pfizer. JAW: Grants or consulting with AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. KD: Employee of AbbVie and may hold stock or options. TG: Employee of AbbVie and may hold stock or options. KK: Employee of AbbVie and may hold stock or options. I-HS: Employee of AbbVie and may hold stock or options. FG: Employee of AbbVie and may hold stock or options. AD: Received research grants, consultancy fees, speaker fees, and other support (medical writing support) from Eli Lilly, Novartis, Pfizer and UCB; research grants, consultancy fees, and other support (medical writing support) from AbbVie, Bristol Myers Squibb, Eli Lilly, and UCB; research grants and consultancy fees from GlaxoSmithKline; consultancy fees and other support (medical writing support) from Janssen; consultancy fees from Bristol Myers Squibb and Celgene; and other support (medical writing support) from Amgen.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Poddubnyy</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Jadon</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mease</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Gladman</surname>
                      <given-names>DD</given-names>
                    </name>
                  </person-group>
                  <article-title>Axial involvement in psoriatic arthritis: An update for rheumatologists</article-title>
                  <source>Semin Arthritis Rheum</source>
                  <year>2021</year>
                  <volume>51</volume>
                  <issue>4</issue>
                  <fpage>880</fpage>
                  <lpage>887</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.semarthrit.2021.06.006</pub-id>
                  <?supplied-pmid 34198146?>
                  <pub-id pub-id-type="pmid">34198146</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chandran</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?</article-title>
                  <source>Curr Opin Rheumatol</source>
                  <year>2019</year>
                  <volume>31</volume>
                  <issue>4</issue>
                  <fpage>329</fpage>
                  <lpage>334</lpage>
                  <pub-id pub-id-type="doi">10.1097/BOR.0000000000000609</pub-id>
                  <?supplied-pmid 31135567?>
                  <pub-id pub-id-type="pmid">31135567</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jadon</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Sengupta</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Nightingale</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lindsay</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Korendowych</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis</article-title>
                  <source>Ann Rheum Dis</source>
                  <year>2017</year>
                  <volume>76</volume>
                  <issue>4</issue>
                  <fpage>701</fpage>
                  <lpage>707</lpage>
                  <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209853</pub-id>
                  <?supplied-pmid 27913376?>
                  <pub-id pub-id-type="pmid">27913376</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gladman</surname>
                      <given-names>DD</given-names>
                    </name>
                  </person-group>
                  <article-title>Axial Psoriatic Arthritis</article-title>
                  <source>Curr Rheumatol Rep</source>
                  <year>2021</year>
                  <volume>23</volume>
                  <issue>6</issue>
                  <fpage>35</fpage>
                  <pub-id pub-id-type="doi">10.1007/s11926-021-00999-8</pub-id>
                  <?supplied-pmid 33909178?>
                  <pub-id pub-id-type="pmid">33909178</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Feld</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ye</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Chandran</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Inman</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Haroon</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort</article-title>
                  <source>Semin Arthritis Rheum</source>
                  <year>2021</year>
                  <volume>51</volume>
                  <issue>2</issue>
                  <fpage>464</fpage>
                  <lpage>468</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.semarthrit.2021.03.007</pub-id>
                  <?supplied-pmid 33774593?>
                  <pub-id pub-id-type="pmid">33774593</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baraliakos</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Coates</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Braun</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>The involvement of the spine in psoriatic arthritis</article-title>
                  <source>Clin Exp Rheumatol</source>
                  <year>2015</year>
                  <volume>33</volume>
                  <issue>5 Suppl 93</issue>
                  <fpage>S31</fpage>
                  <lpage>S35</lpage>
                  <?supplied-pmid 26471338?>
                  <pub-id pub-id-type="pmid">26471338</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mease</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Palmer</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kavanaugh</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pandurengan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Ritchlin</surname>
                      <given-names>CT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry</article-title>
                  <source>J Rheumatol</source>
                  <year>2018</year>
                  <volume>45</volume>
                  <issue>10</issue>
                  <fpage>1389</fpage>
                  <lpage>1396</lpage>
                  <pub-id pub-id-type="doi">10.3899/jrheum.171094</pub-id>
                  <?supplied-pmid 29961691?>
                  <pub-id pub-id-type="pmid">29961691</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Feld</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ye</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Chandran</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Inman</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Haroon</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?</article-title>
                  <source>Rheumatology (Oxford)</source>
                  <year>2020</year>
                  <volume>59</volume>
                  <issue>6</issue>
                  <fpage>1340</fpage>
                  <lpage>1346</lpage>
                  <pub-id pub-id-type="doi">10.1093/rheumatology/kez457</pub-id>
                  <?supplied-pmid 31593590?>
                  <pub-id pub-id-type="pmid">31593590</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burmester</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Kremer</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Kivitz</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bessette</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial</article-title>
                  <source>Lancet</source>
                  <year>2018</year>
                  <volume>391</volume>
                  <issue>10139</issue>
                  <fpage>2503</fpage>
                  <lpage>2512</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31115-2</pub-id>
                  <?supplied-pmid 29908669?>
                  <pub-id pub-id-type="pmid">29908669</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Genovese</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Fleischmann</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Combe</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Rubbert-Roth</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial</article-title>
                  <source>Lancet</source>
                  <year>2018</year>
                  <volume>391</volume>
                  <issue>10139</issue>
                  <fpage>2513</fpage>
                  <lpage>2524</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31116-4</pub-id>
                  <?supplied-pmid 29908670?>
                  <pub-id pub-id-type="pmid">29908670</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fleischmann</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Pangan</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>IH</given-names>
                    </name>
                    <name>
                      <surname>Mysler</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bessette</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Peterfy</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind</article-title>
                  <source>Randomized Controlled Trial Arthritis Rheumatol</source>
                  <year>2019</year>
                  <volume>71</volume>
                  <issue>11</issue>
                  <fpage>1788</fpage>
                  <lpage>1800</lpage>
                  <?supplied-pmid 31287230?>
                  <pub-id pub-id-type="pmid">31287230</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smolen</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Pangan</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Emery</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Rigby</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Tanaka</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Vargas</surname>
                      <given-names>JI</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study</article-title>
                  <source>Lancet</source>
                  <year>2019</year>
                  <volume>393</volume>
                  <issue>10188</issue>
                  <fpage>2303</fpage>
                  <lpage>2311</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(19)30419-2</pub-id>
                  <?supplied-pmid 31130260?>
                  <pub-id pub-id-type="pmid">31130260</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Vollenhoven</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Takeuchi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Pangan</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Friedman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mohamed</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind</article-title>
                  <source>Active Comparator-Controlled Trial Arthritis Rheumatol</source>
                  <year>2020</year>
                  <volume>72</volume>
                  <issue>10</issue>
                  <fpage>1607</fpage>
                  <lpage>1620</lpage>
                  <?supplied-pmid 32638504?>
                  <pub-id pub-id-type="pmid">32638504</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fleischmann</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Mysler</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bessette</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Peterfy</surname>
                      <given-names>CG</given-names>
                    </name>
                    <name>
                      <surname>Durez</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Tanaka</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study</article-title>
                  <source>RMD Open</source>
                  <year>2022</year>
                  <volume>8</volume>
                  <issue>1</issue>
                  <fpage>e002012</fpage>
                  <pub-id pub-id-type="doi">10.1136/rmdopen-2021-002012</pub-id>
                  <?supplied-pmid 35121639?>
                  <pub-id pub-id-type="pmid">35121639</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <mixed-citation publication-type="other">van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515–23.</mixed-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van der Heijde</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>IH</given-names>
                    </name>
                    <name>
                      <surname>Pangan</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Deodhar</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Maksymowych</surname>
                      <given-names>WP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial</article-title>
                  <source>Lancet</source>
                  <year>2019</year>
                  <volume>394</volume>
                  <issue>10214</issue>
                  <fpage>2108</fpage>
                  <lpage>2117</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(19)32534-6</pub-id>
                  <?supplied-pmid 31732180?>
                  <pub-id pub-id-type="pmid">31732180</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Deodhar</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Poddubnyy</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Maksymowych</surname>
                      <given-names>WP</given-names>
                    </name>
                    <name>
                      <surname>van der Heijde</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>TH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>
                  <source>Lancet</source>
                  <year>2022</year>
                  <volume>400</volume>
                  <issue>10349</issue>
                  <fpage>369</fpage>
                  <lpage>379</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(22)01212-0</pub-id>
                  <?supplied-pmid 35908570?>
                  <pub-id pub-id-type="pmid">35908570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rubbert-Roth</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Enejosa</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Pangan</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Haraoui</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Rischmueller</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Khan</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis</article-title>
                  <source>N Engl J Med</source>
                  <year>2020</year>
                  <volume>383</volume>
                  <issue>16</issue>
                  <fpage>1511</fpage>
                  <lpage>1521</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2008250</pub-id>
                  <?supplied-pmid 33053283?>
                  <pub-id pub-id-type="pmid">33053283</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van der Heijde</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Deodhar</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Maksymowych</surname>
                      <given-names>WP</given-names>
                    </name>
                    <name>
                      <surname>Sieper</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>TH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension</article-title>
                  <source>RMD Open</source>
                  <year>2022</year>
                  <volume>8</volume>
                  <issue>2</issue>
                  <fpage>e002280</fpage>
                  <pub-id pub-id-type="doi">10.1136/rmdopen-2022-002280</pub-id>
                  <?supplied-pmid 35896281?>
                  <pub-id pub-id-type="pmid">35896281</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McInnes</surname>
                      <given-names>IB</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Magrey</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Merola</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kishimoto</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis</article-title>
                  <source>N Engl J Med</source>
                  <year>2021</year>
                  <volume>384</volume>
                  <issue>13</issue>
                  <fpage>1227</fpage>
                  <lpage>1239</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2022516</pub-id>
                  <?supplied-pmid 33789011?>
                  <pub-id pub-id-type="pmid">33789011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mease</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Lertratanakul</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Papp</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Tsuji</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2</article-title>
                  <source>Ann Rheum Dis</source>
                  <year>2020</year>
                  <volume>80</volume>
                  <fpage>312</fpage>
                  <lpage>320</lpage>
                  <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-218870</pub-id>
                  <?supplied-pmid 33272960?>
                  <pub-id pub-id-type="pmid">33272960</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <mixed-citation publication-type="other">Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, et al. Long-term Efficacy and Safety of Upadacitinib in Patients With Psoriatic Arthritis Refractory to Biologic Therapies: 2-year Results From the Phase 3 SELECT-PsA 2 Study [abstract]. Ann Rheum Dis. 2022;81(Suppl 1):836–7.</mixed-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <mixed-citation publication-type="other">McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Haaland D, et al. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. Rheumatol Ther. 2023;10(1):275–92.</mixed-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taylor</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Gladman</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Helliwell</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Marchesoni</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mease</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Mielants</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Classification criteria for psoriatic arthritis: development of new criteria from a large international study</article-title>
                  <source>Arthritis Rheum</source>
                  <year>2006</year>
                  <volume>54</volume>
                  <issue>8</issue>
                  <fpage>2665</fpage>
                  <lpage>2673</lpage>
                  <pub-id pub-id-type="doi">10.1002/art.21972</pub-id>
                  <?supplied-pmid 16871531?>
                  <pub-id pub-id-type="pmid">16871531</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baraliakos</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Gossec</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Pournara</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Jeka</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mera-Varela</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>D'Angelo</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial</article-title>
                  <source>Ann Rheum Dis</source>
                  <year>2021</year>
                  <volume>80</volume>
                  <issue>5</issue>
                  <fpage>582</fpage>
                  <lpage>590</lpage>
                  <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-218808</pub-id>
                  <?supplied-pmid 33334727?>
                  <pub-id pub-id-type="pmid">33334727</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <mixed-citation publication-type="other">AbbVie. RINVOQ® (upadacitinib) [Prescribing Information] [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.rxabbvie.com/pdf/rinvoq_pi.pdf">https://www.rxabbvie.com/pdf/rinvoq_pi.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Deodhar</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>van der Heijde</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Sieper</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Van den Bosch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Maksymowych</surname>
                      <given-names>WP</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>TH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension</article-title>
                  <source>Arthritis Rheumatol</source>
                  <year>2022</year>
                  <volume>74</volume>
                  <issue>1</issue>
                  <fpage>70</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1002/art.41911</pub-id>
                  <?supplied-pmid 34196498?>
                  <pub-id pub-id-type="pmid">34196498</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van der Heijde</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Baraliakos</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Sieper</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Deodhar</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Inman</surname>
                      <given-names>RD</given-names>
                    </name>
                    <name>
                      <surname>Kameda</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial</article-title>
                  <source>Ann Rheum Dis</source>
                  <year>2022</year>
                  <volume>0</volume>
                  <fpage>1</fpage>
                  <lpage>9</lpage>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mease</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Helliwell</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Gladman</surname>
                      <given-names>DD</given-names>
                    </name>
                    <name>
                      <surname>Poddubnyy</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Baraliakos</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Chakravarty</surname>
                      <given-names>SD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies</article-title>
                  <source>Lancet Rheumatology</source>
                  <year>2021</year>
                  <volume>3</volume>
                  <issue>10</issue>
                  <fpage>e715</fpage>
                  <lpage>e723</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2665-9913(21)00105-3</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McInnes</surname>
                      <given-names>IB</given-names>
                    </name>
                    <name>
                      <surname>Kato</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Magrey</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Merola</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Kishimoto</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Pacheco-Tena</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study</article-title>
                  <source>RMD Open</source>
                  <year>2021</year>
                  <volume>7</volume>
                  <issue>3</issue>
                  <fpage>e001838</fpage>
                  <pub-id pub-id-type="doi">10.1136/rmdopen-2021-001838</pub-id>
                  <?supplied-pmid 34663636?>
                  <pub-id pub-id-type="pmid">34663636</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mease</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Lertratanakul</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Papp</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>van den Bosch</surname>
                      <given-names>FE</given-names>
                    </name>
                    <name>
                      <surname>Tsuji</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dokoupilova</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study</article-title>
                  <source>Rheumatol Ther</source>
                  <year>2021</year>
                  <volume>8</volume>
                  <issue>2</issue>
                  <fpage>903</fpage>
                  <lpage>919</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40744-021-00305-z</pub-id>
                  <?supplied-pmid 33913086?>
                  <pub-id pub-id-type="pmid">33913086</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <mixed-citation publication-type="other">Deodhar A, Ranza R, Ganz F, Gao T, Anderson J, Östör A. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement [abstract]. Arthritis Rheumatol. 2020;72(suppl 10).</mixed-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <mixed-citation publication-type="other">Baraliakos X, Ranza R, Ostor A, Ciccia F, Coates L, Rednic S, et al. Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies [abstract]. Arthritis Rheumatol. 2021;73(suppl 10).</mixed-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nash</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Richette</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Gossec</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Marchesoni</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ritchlin</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kato</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis</article-title>
                  <source>Rheumatology (Oxford)</source>
                  <year>2021</year>
                  <volume>00</volume>
                  <fpage>1</fpage>
                  <lpage>12</lpage>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
